查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1820360

神经生物标记市场规模、份额、趋势及预测（按类型、应用、最终用途和地区），2025 年至 2033 年

Neurological Biomarkers Market Size, Share, Trends and Forecast by Type, Application, End Use, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球神经系统生物标记市场规模达100亿美元。展望未来， IMARC Group预测，到2033年，该市场规模将达到251亿美元，2025-2033年期间的复合年增长率为10.8%。目前，北美占据神经系统生物标记市场份额的主导地位，到2024年将超过41.6%，这得益于神经系统疾病发病率的上升、健全的医疗保健体係以及高额科研投入的加速。生物标记在早期诊断中的应用日益增多、临床试验的扩大以及生物技术公司与研究机构之间为开发创新神经系统疗法而不断加强的合作，进一步推动了市场的成长。

中风、运动神经元疾病 (MND)、阿兹海默症 (AD)、帕金森氏症 (PD) 和亨廷顿舞蹈症 (HD) 等神经系统疾病的发生率不断上升，这加剧了对更快药物开发的需求。这是推动市场成长的主要因素之一，因为生物标记有助于衡量新药和治疗策略的疗效。微创手术和个人化医疗的日益普及是另一个主要的成长诱因。除此之外，由于各种神经系统疾病具有共同的标准特征，因此对多种生物标记的需求也在增加，以区分特定疾病及其亚型。此外，质谱和成像程序的进步使得能够更快地评估大量生化标记和大脑结构变化。这一点，加上数位生物标记的引入和临床试验数量的增加，预计将在未来几年推动市场的成长。

美国在全球神经生物标记市场中占有突出地位，这得益于其先进的医疗基础设施和对医学研究的高度重视。随着阿兹海默症和帕金森氏症等神经系统疾病的高发生率，对创新诊断工具的需求日益增长。例如，根据产业报告，美国约有 100 万人口患有帕金森氏症，预计到 2030 年这一数字将上升到 120 万人。此外，美国受益于对生物技术和製药行业的大量投资，促进了神经生物标记的开发和商业化。此外，监管支援和大量配备尖端技术的医院实验室进一步促进了市场成长。美国在推动个人化医疗和改善早期疾病检测和管理方面仍然是关键参与者。

神经生物标记市场趋势：

神经系统疾病发生率上升

世界卫生组织（WHO）2024年的报告强调，神经系统疾病已成为疾病和残疾的首要原因。据报道，1990年，因神经系统疾病导致的残疾、疾病或早逝造成的总体负担——残疾调整生命年（DALY）——总体增长了18%。这些都与阿兹海默症、帕金森氏症以及多发性硬化症（MS）发病率的增长有关。此外，全球人口老化也增加了对用于疾病检测和监测的生物标记诊断工具的需求，从而推动了全球神经系统生物标记市场的成长。

生物技术和基因组研究的进展

基因组学、蛋白质组学和分子生物学的进步为开发更精准、更精确的神经系统疾病生物标记物做出了巨大贡献。事实上，这些进步不仅提高了诊断的精准度，也促进了疾病的早期发现和更好地监测治疗效果。根据世界卫生组织2023年2月发布的一篇文章，全球每年新增近500万人被诊断出患有癫痫，迫切需要精准的诊断技术。此外，由于老年人口中阿兹海默症的增加，以及早期发现、监测和定向治疗的持续成长，预计将进一步扩大市场。

个人化医疗需求不断成长

个人化医疗正在迅速超越其他药物成分，在个人化医疗中，干预措施和治疗方法是根据患者的个人需求、基于患者的基因组成和各种疾病的生物标誌物而定制和製定的。神经生物标记是显着促进这种个人化治疗的关键组成部分，从而积极支持识别疾病特异性分子特征和改进各种治疗方法。因此，个人化医疗预计将促进全球神经生物标记市场的成长。根据阿兹海默症协会的数据，目前全球有 5,500 万人患有痴呆症；预计到 2030 年，这一数字将上升到 7,800 万，到 2050 年将上升到近 1.39 亿。此类疾病病例的显着增加凸显了对更精确的标靶治疗和诊断工具的不可或缺的需求，这进一步增加了神经生物标记在神经系统疾病的管理和治疗中的需求。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球神经生物标记市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场细分：依类型

  • 基因组生物标记
  • 蛋白质体生物标记
  • 代谢组学生物标誌物
  • 成像生物标记
  • 其他的

第七章：市场区隔：依应用

  • 阿兹海默症
  • 帕金森氏症
  • 多发性硬化症
  • 自闭症谱系障碍
  • 其他的

第 8 章：市场区隔：最终用途别

  • 医院实验室
  • 临床诊断中心
  • 研究机构
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Acumen Pharmaceuticals Inc.
    • Athena Diagnostics (Quest Diagnostics)
    • Banyan Biomarkers Inc.
    • Bio-Rad Laboratories Inc.
    • Immunarray Pvt. Ltd.
    • Myriad Rbm Inc. (Myriad Genetics Inc.)
    • Proteome Sciences Plc
    • Thermo Fisher Scientific Inc.
Product Code: SR112025A3181

The global neurological biomarkers market size was valued at USD 10.0 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 25.1 Billion by 2033, exhibiting a CAGR of 10.8% during 2025-2033. North America currently dominates the neurological biomarkers market share, of over 41.6% in 2024, driven by escalating incidents of neurological conditions, robust healthcare systems, and accelerated high research investments. The growth of the market is further fueled by an increase in biomarkers adoption for early diagnosis, expanded clinical trials, and growing collaborations between biotech companies and research organizations to develop innovative neurological treatments.

The rising occurrence of neurological disorders, such as stroke, motor neuron disease (MND), Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), is escalating the need for faster drug development. This represents one of the primary factors impelling the market growth as biomarkers help measure the efficacy of new drugs and therapeutic strategies. The increasing adoption of minimally invasive procedures and personalized medicines are acting as another major growth-inducing factor. Apart from this, as various neurological disorders share standard features, there is an increase in the demand for multiple biomarkers to differentiate specific diseases and their sub-types. Moreover, advancements in mass spectrometry and imaging procedures enable faster evaluation of large numbers of biochemical markers and structural changes in the brain. This, along with the introduction of digital biomarkers and the rising number of clinical trials, is anticipated to propel the growth of the market in the coming years.

The United States holds a prominent position in the global neurological biomarkers market share, driven by its advanced healthcare infrastructure and strong focus on medical research. With a high prevalence of neurological disorders, including Alzheimer's and Parkinson's disease, there is a growing demand for innovative diagnostic tools. For instance, as per industry reports, around 1 million U.S. population is affected with Parkinson's disease, and this count is anticipated to elevate to 1.2 million by the year 2030. Furthermore, the U.S. benefits from significant investments in biotechnology and pharmaceutical industries, fostering the development and commercialization of neurological biomarkers. Additionally, regulatory support and a large base of hospital laboratories equipped with cutting-edge technologies further enhance market growth. The U.S. remains a key player in advancing personalized medicine and improving early disease detection and management.

Neurological Biomarkers Market Trends:

Rising Incidence of Neurological Disorders

As highlighted by a report from WHO in 2024, neurological disorders have become the number one cause of ill health and disability. According to reports, DALYs of overall burden due to disability, ill health, or early death as a result of neurological disorders in 1990 has been stated to be the 18-percentage increase in general. These all are attributed with the growth incidence of Alzheimer, Parkinson's as well as multiple sclerosis (MS). In addition to this, the aging population in the world increases the demand for diagnostic tools with biomarkers in the detection and monitoring of diseases, thereby propelling the neurological biomarkers market growth globally.

Advancements in Biotechnology and Genomic Research

Advances in genomics, proteomics, and molecular biology have contributed much towards developing far more accurate and precise biomarkers for neurologic disorders. Actually, these advances have enhanced diagnostic precision as well as facilitated early detection of diseases and better monitoring of responses to treatment. According to an article from the WHO released in February 2023, almost 5 million people worldwide are newly diagnosed each year with epilepsy, with the call for precise diagnostic techniques. In addition, the elderly population's increase in Alzheimer's disease is predicted to further expand the market due to the continuing growth in early detection, monitoring, and directed treatments.

Increasing Demand for Personalized Medicine

Personalized medicine is rapidly surpassing other pharmaceutical components, in which interventions and treatment methods are customized and formulated as per the individual needs of a patient, based on their genetic makeup and biomarkers of various disease. Neurological biomarkers are the crucial components that significantly facilitate this kind of personalized treatment, thereby actively supporting the identification of disease-specific molecular signatures and refinement of varied therapeutic methods. As a result, personalized medicine is anticipated to bolster the expansion of the neurological biomarkers market forecast globally. According to the Alzheimer's Association, currently 55 million people worldwide are suffering from dementia; this number is suspected to elevate to 78 million by the year 2030 and to almost 139 million by 2050. The notable increase in cases of such conditions highlights the indispensable requirement for more precise targeted therapies as well as diagnostic tools, further escalating the need for neurological biomarkers in both the management and treatment of neurological disorders.

Neurological Biomarkers Industry Segmentation:

Analysis by Type:

  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Metabolomic Biomarkers
  • Imaging Biomarkers
  • Others

Based on the neurological biomarkers market forecast, proteomic biomarkers lead the market with around 31.2% of market share in 2024, chiefly because of their excellent capability to locate disease-associated proteins and their role in comprehending complicated neurological conditions. Such biomarkers are critical in identifying particular protein alterations in the brain that can play the role of early indicators for neurodegenerative disorders, mainly including Parkinson's and Alzheimer's disease. Besides, the growing emphasis on personalized therapies as well as precision medicine has significantly bolstered the requirement for proteomic biomarkers, mainly because they foster targeted treatment methodologies. In addition, active innovations in protein analysis methods and mass spectrometry have facilitated more dependable and precise biomarker discovery. Furthermore, the amplifying acknowledgement of proteomic biomarkers' potential to substantially improve diagnostic accuracy, combined with their feasibility in disease assessment and prognosis, guarantees that this type continues to dominate the market. The incorporation of proteomic biomarkers with several other diagnostic technologies further fortifies their position as a crucial driver propelling the neurological biomarkers market demand.

Analysis by Application:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Autism Spectrum Disorders
  • Others

Alzheimer's disease holds the largest market share by application in the global neurological biomarkers market, mainly influenced by its accelerated prevalence and the urgent demand for efficient management and early diagnosis. As the most prevalent type of dementia, Alzheimer's exhibits notable healthcare challenges worldwide, with a rapid increase in geriatric population fueling its escalating incidence. Early detection of Alzheimer's disease enables for timely interventions, likely reducing disease progression and enhancing patient outcomes. Moreover, biomarkers, including tau proteins and amyloid-beta, coupled with rising blood-based markers, are crucial in diagnosing Alzheimer's at its early phases. In addition, the requirement for non-invasive, precise biomarkers for Alzheimer's diagnosis has resulted in a constant innovation and research initiatives. Furthermore, biomarkers are requisite in assessing treatment effectiveness, aiding in tailoring personalized therapeutic tactics. Given the profound economic as well as social impacts of Alzheimer's disease, its management via biomarkers remains a leading priority in neurological healthcare and research, straightening its leading market share and contributing to a positive neurological biomarkers market outlook.

Analysis by End Use:

  • Hospital Laboratories
  • Clinical Diagnostic Centers
  • Research Organizations
  • Others

Hospital laboratories represent the largest segment by end use in the global neurological biomarkers market, as they play a central role in the diagnosis and monitoring of neurological conditions. These laboratories are equipped with advanced diagnostic technologies, enabling the efficient testing and analysis of neurological biomarkers, which are essential for disease detection and prognosis. With the rising incidence of neurological disorders such as Alzheimer's, Parkinson's, and multiple sclerosis, hospital laboratories are increasingly relied upon for early diagnosis and treatment decision-making. Their ability to provide accurate, timely results supports improved patient outcomes and aids in the development of personalized treatment plans. Furthermore, hospital laboratories benefit from regulatory approvals and the integration of new biomarker assays, which enhance their diagnostic capabilities. Moreover, as healthcare systems evolve, hospital laboratories remain at the forefront of leveraging neurological biomarkers to address the growing burden of neurological diseases, thus driving their significant share in the market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 41.6%, driven by magnifying cases prevalence of neurological conditions, well-established healthcare infrastructure, and innovative research abilities. For instance, as per industry reports, by 2030, in Canada, around 1 million people are expected to be living with dementia, an umbrella term for memory-related neurological disorder encompassing Alzheimer's, with projections exceeding 1.7 million by 2050. Moreover, the region notably profits from heavy investments in pharmaceuticals and biotechnology sectors, facilitating advancements in diagnostic technologies as well as biomarker discovery. In additionally, North America's amplifying need for early detection and customized treatment options for neurological conditions, mainly encompassing Parkinson's and Alzheimer's, further boosts market growth. The beneficial regulatory ecosystem and presence of leading players in Canada and the U.S. also fuel the region's domination in the neurological biomarkers industry.

Key Regional Takeaways:

United States Neurological Biomarkers Market Analysis

In 2024, United States accounted for the 91.00% of the market share in North America. The neurological disorders market in the United States is being heavily driven by an increase in the prevalence of neurological disorders. Stroke has been estimated to be the third cause of death in the country, and Parkinson's disease has been documented to have around 1 million affected individuals, as per reports. The increasing cases for other neurological diseases, such as Alzheimer's and epilepsy, also look at the rising demand for accurate diagnostics and biomarkers. All of these requirements-the need for early detection, the use of individualized treatment plans, and ongoing monitoring of the disease process-propel the implementation of neurological biomarkers. Since the field of genomics, proteomics, and molecular biology is continuously progressing, new and more specific biomarkers are found, thus better diagnostic accuracy and treatment monitoring. Increasing number of the geriatric population along with an ever-growing awareness toward neurological conditions, in turn, are anticipated to continue propelling demand for biomarkers in the United States-ensuring it a critical role in patient outcome enhancement and disease management.

Europe Neurological Biomarkers Market Analysis

The neurological conditions are increasingly developing in Europe and are the greatest driver for this market. Alzheimer's Society recently reported that around 850,000 people living in the UK were suffering from dementia in 2019. This is how the incidence of neurological disorders increases in the region. This means, on average, 1 of every 14 individuals above 65 years suffer from dementia- a statistic underlining the growing need for highly advanced diagnostic tools. With aging populations on the rise, more neurological biomarkers that can help to detect diseases earlier, diagnose it, and then monitor it including Alzheimer's disease, Parkinson's disease, or multiple sclerosis is expected to continue rising. Advances in molecular biology, genomics, and proteomics are enabling the discovery of more specific and reliable biomarkers, further fueling the adoption of these diagnostic tools. In the coming years, the increasing burden of neurological diseases in Europe is expected to drive the market for neurological biomarkers.

Asia Pacific Neurological Biomarkers Market Analysis

The Asia Pacific neurological biomarkers market is booming because of the increased incidence and prevalence of neurological disorders such as Parkinson's Disease (PD). The NIH estimated that from 1990 to 2021, the incidence of PD in Asia increased by 198.01%, while its prevalence rose by 284.35%, mortality by 111.27%, and disability-adjusted life years (DALY) by 144.45%. These disturbing statistics draw attention to an ever-increasing burden of neurological conditions in the region. Additionally, the statistics point to a significant growing gender gap where males constantly demonstrate a more significant burden than females. Due to the rise in the number of aging individuals in Asia Pacific, the requirements for early diagnosis and monitoring of neurological diseases will continue to increase over time. This trend drives the need for advanced biomarkers to aid in the detection and tracking of conditions like PD, Alzheimer's, and other neurodegenerative diseases, further propelling the market for neurological biomarkers in the region.

Latin America Neurological Biomarkers Market Analysis

The Latin America neurological biomarkers market is expected to undergo a significant boost with the surging prevalence of dementia in this region. Within the last ten years, many Latin American nations have reported an increase in prevalence rates of dementia from 6.2% to 12.1% among the older population aged 65 and more. The NIH estimates that dementia will affect the region most within the decade ahead, with data for the year 2022. The burden of healthcare is expected to increase manifolds with dementia patient count increasing close to four fold by 2050. Such an alarming rise of dementia further brings forth the demand for advanced diagnostic tools that include neurological biomarkers in the detection and monitoring of such conditions. The growth of the aging population and the increasing prevalence of neurodegenerative diseases have fueled the growth of the neurological biomarkers market in Latin America, as the need for efficient biomarkers for early diagnosis and personalized treatment continues to grow.

Middle East and Africa Neurological Biomarkers Market Analysis

The neurological biomarkers market in the Middle East and Africa is experiencing an increase due to the increasing dementia burden, mainly in low and middle-income countries. Dementia prevalence in this region ranges between 2.3% and 20.0%, and the incidence rates are at 13.3 per 1000 person-years, as NIH data shows for 2023. As the continent of Africa accelerates its population's urbanization and aging population, the statistics of dementia increases, leading to higher mortality counts, especially for regions that transform rapidly. There is a trend of increased occurrence of dementia patients, which demands more healthcare systems worldwide, thus presenting a growing interest in effective solutions for diagnosis in the form of neurological biomarkers. These biomarkers play a significant role in the early detection and follow-up of neurodegenerative diseases like dementia. This is, therefore, fueling the need for advanced diagnostic tools in the Middle East and Africa. Other factors driving the growth of this market in this region include rising healthcare burden and an aging population.

Competitive Landscape:

The market is extensively competitive, exhibiting a fusion of diagnostic solution providers, established pharmaceutical firms, and biotechnology companies. Leading players are currently emphasizing on tactical acquisition, partnerships, and research investments to proliferate their product portfolios. Moreover, industry giants, including Abbott Laboratories and Siemens Healthineers, utilize leading-edge technologies such as neuroimaging, genomic sequencing, and proteomics to offer upgraded products. For instance, in October 2024, Siemens Healthineers announced becoming the fisrt company to recieve Health Canada Licensing for its blood-based biomarker Neurofilament Light Chain (NfL), which is developed particularly for diagnosing and managing Multiple Sclerosis, a severe neurological condition. The company announced the commercial availability of this biomarker in Canada market. In addition, smaller, innovative firms are also establishing themselves gradually with customized medicine solutions and specialized biomarker assays. Furthermore, competitive tactics gravitate on designing novel biomarkers for various neurological disorders, including Parkinson's and Alzheimer's diseases, improving diagnostic precision, and enhancing patient outcomes.

The report provides a comprehensive analysis of the competitive landscape in the neurological biomarkers market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Acumen Pharmaceuticals Inc.
  • Athena Diagnostics (Quest Diagnostics)
  • Banyan Biomarkers Inc.
  • Bio-Rad Laboratories Inc.
  • Immunarray Pvt. Ltd.
  • Myriad Rbm Inc. (Myriad Genetics Inc.)
  • Proteome Sciences Plc
  • Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1.How big is the neurological biomarkers market?
  • 2.What is the expected growth rate of the global Neurological Biomarkers market during 2025-2033?
  • 3.What are the trends in the neurology market?
  • 4.Which segment accounted for the largest neurological biomarkers market share?
  • 5.Which is the fastest growing region in neurological biomarkers market?
  • 6.Which are the top companies to hold the market share in neurological biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neurological Biomarkers Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Genomic Biomarkers
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Proteomic Biomarkers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Metabolomic Biomarkers
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Imaging Biomarkers
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Alzheimer's Disease
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Parkinson's Disease
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Multiple Sclerosis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Autism Spectrum Disorders
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Hospital Laboratories
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinical Diagnostic Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Organizations
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Acumen Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Athena Diagnostics (Quest Diagnostics)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Banyan Biomarkers Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Bio-Rad Laboratories Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Immunarray Pvt. Ltd.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Myriad Rbm Inc. (Myriad Genetics Inc.)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Proteome Sciences Plc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Thermo Fisher Scientific Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Neurological Biomarkers Market: Major Drivers and Challenges
  • Figure 2: Global: Neurological Biomarkers Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Neurological Biomarkers Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Neurological Biomarkers Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Neurological Biomarkers Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Neurological Biomarkers Market: Breakup by End Use (in %), 2024
  • Figure 7: Global: Neurological Biomarkers Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Neurological Biomarkers (Genomic Biomarkers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Neurological Biomarkers (Genomic Biomarkers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Neurological Biomarkers (Proteomic Biomarkers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Neurological Biomarkers (Proteomic Biomarkers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Neurological Biomarkers (Metabolomic Biomarkers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Neurological Biomarkers (Metabolomic Biomarkers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Neurological Biomarkers (Imaging Biomarkers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Neurological Biomarkers (Imaging Biomarkers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Neurological Biomarkers (Alzheimer's Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Neurological Biomarkers (Alzheimer's Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Neurological Biomarkers (Parkinson's Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Neurological Biomarkers (Parkinson's Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Neurological Biomarkers (Multiple Sclerosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Neurological Biomarkers (Multiple Sclerosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Neurological Biomarkers (Autism Spectrum Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Neurological Biomarkers (Autism Spectrum Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Neurological Biomarkers (Hospital Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Neurological Biomarkers (Hospital Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Neurological Biomarkers (Clinical Diagnostic Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Neurological Biomarkers (Clinical Diagnostic Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Neurological Biomarkers (Research Organizations) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Neurological Biomarkers (Research Organizations) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Neurological Biomarkers (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Neurological Biomarkers (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: North America: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: North America: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: United States: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: United States: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Canada: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Canada: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Asia-Pacific: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Asia-Pacific: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: China: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: China: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Japan: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Japan: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: India: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: India: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: South Korea: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: South Korea: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Australia: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Australia: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Indonesia: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Indonesia: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Others: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Europe: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Europe: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Germany: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Germany: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: France: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: France: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: United Kingdom: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: United Kingdom: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Italy: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Italy: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Spain: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Spain: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Russia: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Russia: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Latin America: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Latin America: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Brazil: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Brazil: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Mexico: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Mexico: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Others: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Others: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Middle East and Africa: Neurological Biomarkers Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Middle East and Africa: Neurological Biomarkers Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Middle East and Africa: Neurological Biomarkers Market: Breakup by Country (in %), 2024
  • Figure 85: Global: Neurological Biomarkers Industry: SWOT Analysis
  • Figure 86: Global: Neurological Biomarkers Industry: Value Chain Analysis
  • Figure 87: Global: Neurological Biomarkers Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Neurological Biomarkers Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Neurological Biomarkers Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Neurological Biomarkers Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 4: Global: Neurological Biomarkers Market Forecast: Breakup by End Use (in Million USD), 2025-2033
  • Table 5: Global: Neurological Biomarkers Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Neurological Biomarkers Market: Competitive Structure
  • Table 7: Global: Neurological Biomarkers Market: Key Players